Oral GLP-1s Won’t Win on Convenience – They’ll Win on CMC
GLP-1 peptides validated the science. CMC will validate the small molecule modality for GLP-1 efficacy, scalability, and access.
False
Advertisement
Related Content
Small Molecules
Small Molecules
Formulation
The Confidentiality Barrier to AI-Enabled Drug Development
July 27, 2026
3 min read
AI can help formulation teams better predict performance and allocate resources, but proprietary data protections remain a critical bottleneck
Small Molecules
Small Molecules
Business & Trends
Why Drug Development Still Lacks Integration
July 21, 2026
4 min read
John McDermott reflects on why early drug development remains fragmented – and how integrated approaches may shorten timelines
Cell & Gene
Drug Delivery
Development & Clinical
In Vivo CAR T: A New Route to Treating Autoimmune Disease
July 13, 2026
6 min read
How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments
Small Molecules
Drug Discovery
Formulation
Reformulating the Future of Small Molecules
June 30, 2026
1 min read
A special collection of recent stories exploring oral dose innovation, API stability, nitrosamine testing, and the evolving science of small molecule medicines